Analysts forecast that Diplomat Pharmacy Inc (NYSE:DPLO) will announce $1.17 billion in sales for the current quarter, Zacks reports. Seven analysts have made estimates for Diplomat Pharmacy’s earnings, with the lowest sales estimate coming in at $1.14 billion and the highest estimate coming in at $1.20 billion. Diplomat Pharmacy reported sales of $1.14 billion during the same quarter last year, which would suggest a positive year over year growth rate of 2.6%. The firm is expected to issue its next quarterly earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Diplomat Pharmacy will report full year sales of $1.17 billion for the current fiscal year, with estimates ranging from $4.47 billion to $4.53 billion. For the next fiscal year, analysts forecast that the firm will report sales of $5.49 billion per share, with estimates ranging from $5.40 billion to $5.60 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Diplomat Pharmacy.
DPLO has been the topic of a number of research reports. Mizuho raised their price target on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 7th. Needham & Company LLC raised their price target on Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, January 8th. Leerink Swann raised their price target on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 7th. BidaskClub downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Deutsche Bank initiated coverage on Diplomat Pharmacy in a research note on Monday, December 4th. They issued a “buy” rating and a $22.00 price target on the stock. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $23.95.
Diplomat Pharmacy (NYSE DPLO) opened at $23.79 on Wednesday. The stock has a market capitalization of $1,659.84, a price-to-earnings ratio of 237.90 and a beta of 1.06. Diplomat Pharmacy has a 52 week low of $13.39 and a 52 week high of $27.78. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its position in Diplomat Pharmacy by 25.0% during the second quarter. Royal Bank of Canada now owns 35,266 shares of the company’s stock valued at $521,000 after purchasing an additional 7,056 shares in the last quarter. Sterling Capital Management LLC purchased a new position in Diplomat Pharmacy during the third quarter valued at $2,283,000. Convergence Investment Partners LLC purchased a new position in Diplomat Pharmacy during the fourth quarter valued at $1,778,000. Nationwide Fund Advisors lifted its position in Diplomat Pharmacy by 46.7% during the third quarter. Nationwide Fund Advisors now owns 156,249 shares of the company’s stock valued at $3,236,000 after purchasing an additional 49,749 shares in the last quarter. Finally, Cortina Asset Management LLC lifted its position in Diplomat Pharmacy by 538.8% during the third quarter. Cortina Asset Management LLC now owns 1,616,792 shares of the company’s stock valued at $33,484,000 after purchasing an additional 1,363,696 shares in the last quarter. Institutional investors own 73.44% of the company’s stock.
WARNING: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/21/1-17-billion-in-sales-expected-for-diplomat-pharmacy-inc-dplo-this-quarter.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.